insitro
Focus: insitro is a machine learning-driven drug discovery biotech focused on neurology, ophthalmology, metabolic diseases, and cell therapy. The company leverages AI/ML platforms to accelerate early-stage therapeutic development.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Open Jobs
14+14 this month
Growing — net +14 jobs in 30d
14 jobs added vs 0 removed. Steady team buildout.
Should You Work at insitro?
AI assessmentinsitro is a high-risk, high-upside platform play suited to ML engineers and computational biologists willing to bet on early-stage AI-driven discovery with no revenue or clinical proof-of-concept yet.
Why Work Here
- Cutting-edge ML/AI application in drug discovery—rare opportunity to build computational biology infrastructure from the ground up
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for insitro
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.